TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences

Reuters

10/08

TransCode <a href="https://laohu8.com/S/LENZ">Therapeutics</a> acquires Polynoma and secures 25 million investment from CK Life Sciences

TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE93003) on October 08, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573092844"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573092844\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573092844?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573092844","market":"nz","top_or_hot":-1,"title":"TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> acquires Polynoma and secures 25 million investment from CK Life Sciences\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE93003) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-08 20:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> acquires Polynoma and secures 25 million investment from CK Life Sciences\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE93003) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL7rMKPn:1","article_id":"2573092844","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573092844","pubTimestamp":1759924947,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.Disclaimer: This news brief was created by Public Technologies  using generative ar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK1161":"生物科技","RNAZ":"TransCode Therapeutics  Inc.","BK1569":"长和系","BK4139":"生物科技","00775":"长江生命科技"},"translate_title":"TransCode Therapeutics收购Polynoma获长江生命科技2500万投资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00775":0.9,"RNAZ":0.9},"content_text":"TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences\n    \n\n        TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE93003) on October 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}